|
[1]
|
Peinert, S., Prince, H.M., Guru, P.M., et al. (2010) Gene-Modified T Cells as Immunotherapy for Multiple Myeloma and Acute Myeloid Leukemia Expressing the Lewis Y Antigen. Gene Therapy, 17, 678-686.
[Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Ritchie, D.S., Neeson, P.J., Khot, A., et al. (2013) Persistence and Efficacy of Second-Generation CAR T Cell against the LeY Antigen in Acute Myeloid Leukemia. Molecular Therapy, 21, 2122-2129.
[Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Mcmillan, S.J. and Crocker, P.R. (2008) CD33-Related Sialic-Acid-Binding Immunoglobulin-Like Lectins in Health and Disease. Carbohydrate Research, 343, 2050-2056.
[Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Dutour, A., Marin, V., Pizzitola, I., et al. (2012) In Vitro and in Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia. Advances in Hematology, 2012, Article ID: 683065.
[Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Wang, Q., Wang, Y., Lv, H., et al. (2015) Treatment of CD33-Directed Chimeric Antigen Receptor-Modified T Cells in One Patient with Relapsed and Refractory Acute Myeloid Leukemia. Molecular Therapy, 23, 184-191.
[Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Minagawa, K., Jamil, M.O., Al-Obaidi, M., et al. (2016) In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS ONE, 11, e166891.
[Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Jordan, C.T., Upchurch, D., Szilvassy, S.J., et al. (2000) The Interleukin-3 Receptor Alpha Chain Is a Unique Marker for Human Acute Myelogenous Leukemia Stem Cells. Leukemia, 14, 1777-1784.
[Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Mardiros, A., Dos, S.C., Mcdonald, T., et al. (2013) T Cells Expressing CD123-Specific Chimeric Antigen Receptors Exhibit Specific Cytolytic Effector Functions and Antitumor Effects against human Acute Myeloid Leukemia. Blood, 122, 3138-3148.
[Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Keyhani, A., Huh, Y.O., Jendiroba, D., et al. (2000) Increased CD38 Expression Is Associated with Favorable Prognosis in Adult Acute Leukemia. Leukemia Research, 24, 153-159.
[Google Scholar] [CrossRef]
|
|
[10]
|
Yoshida, T., Mihara, K., Takei, Y., et al. (2016) All-Trans Retinoic Acid Enhances Cytotoxic Effect of T Cells with an Anti-CD38 Chimeric Antigen Receptor in Acute Myeloid Leukemia. Clinical & Translational Immunology, 5, e116.
[Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Legras, S., Gunthert, U., Stauder, R., et al. (1998) A Strong Expression of CD44-6v Correlates with Shorter Survival of Patients with Acute Myeloid Leukemia. Blood, 91, 3401-3413.
[Google Scholar] [CrossRef]
|
|
[12]
|
Casucci, M., Nicolis Di Robilant, B., Falcone, L., et al. (2013) CD44v6-Targeted T Cells Mediate Potent Antitumor Effects against Acute Myeloid Leukemia and Multiple Myeloma. Blood, 122, 3461-3472.
[Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Wang, H., Kaur, G., Sankin, A.I., Chen, F., Guan, F. and Zang, X. (2019) Immune Checkpoint Blockade and CAR-T Cell Therapy in Hematologic Malignancies. Journal of Hematology & Oncology, 12, 59.
[Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Kaufmann, Y., Amariglio, N., Rosenthal, E., Hirsch, Y.J., Many, A. and Rechavi, G. (2005) Proliferation Response of Leukemic Cells to CD70 Ligation Oscillates with Recurrent Remission and Relapse in a Low-Grade Lymphoma. The Journal of Immunology, 175, 6940-6947.
[Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Sauer, T., Parikh, K., Sharma, S., Omer, B., Sedloev, D., Chen, Q., Angenendt, L., Schliemann, C., Schmitt, M., Müller-Tidow, C., Gottschalk, S. and Rooney, C.M. (2021) CD70-Specific CAR T Cells Have Potent Activity against Acute Myeloid Leukemia without HSC Toxicity. Blood, 138, 318-330.
[Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Salih, H.R., Antropius, H., Gieseke, F., et al. (2003) Functional Expression and Release of Ligands for the Activating Immunoreceptor NKG2D in Leukemia. Blood, 102, 1389-1396.
[Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Murad, J. (2016) Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma.
|
|
[18]
|
Pan, X.Q., Zheng, X., Shi, G., et al. (2002) Strategy for the Treatment of Acute Myelogenous Leukemia Based on Folate Receptor Beta-Targeted Liposomal Doxorubicin Combined with Receptor Induction Using All-Trans Retinoic Acid. Blood, 100, 594-602.
[Google Scholar] [CrossRef]
|
|
[19]
|
Wang, H., Zheng, X., Behm, F.G., et al. (2000) Differentiation-Independent Retinoid Induction of Folate Receptor Type Beta, a Potential Tumor Target in Myeloid Leukemia. Blood, 96, 3529-3536.
[Google Scholar] [CrossRef]
|
|
[20]
|
Lynn, R.C., Poussin, M., Kalota, A., et al. (2015) Targeting of Folate Receptor Beta on Acute Myeloid Leukemia Blasts with Chimeric Antigen Receptor-Expressing T Cells. Blood, 125, 3466-3476.
[Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Lynn, R.C., Feng, Y., Schutsky, K., et al. (2016) High-Affinity FRbeta-Specific CAR T Cells Eradicate AML and Normal Myeloid Lineage without HSC Toxicity. Leukemia, 30, 1355-1364.
[Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Chen, L., Mao, H., Zhang, J., et al. (2017) Targeting FLT3 by Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Leukemia, 31, 1830-1834.
[Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Kiyoi, H., Ohno, R., Ueda, R., et al. (2002) Mechanism of Constitutive Activation of FLT3 with Internal Tandem Duplication in the Juxtamembrane Domain. Oncogene, 21, 2555-2563.
[Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Marofi, F., Rahman, H.S., Al-Obaidi, Z.M.J., Jalil, A.T., Abdelbasset, W.K., Suksatan, W., Dorofeev, A.E., Shomali, N., Chartrand, M.S., Pathak, Y., Hassanzadeh, A., Baradaran, B., Ahmadi, M., Saeedi, H., Tahmasebi, S. and Jarahian, M. (2021) Novel CAR T Therapy Is a Ray of Hope in the Treatment of Seriously Ill AML Patients. Stem Cell Research & Therapy, 12, 465.
[Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Laborda, E., Mazagova, M., Shao, S., et al. (2017) Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia. International Journal of Molecular Sciences, 18, 2259.
[Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Zhang, H., Wang, P., Li, Z., He, Y., Gan, W. and Jiang, H. (2021) Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 27, 3549-3555.
[Google Scholar] [CrossRef]
|
|
[27]
|
Nakazawa, Y., Matsuda, K., Kurata, T., et al. (2016) Anti-Proliferative Effects of T Cells Expressing a Ligand-Based Chimeric Antigen Receptor against CD116 on CD34+ Cells of Juvenile Myelomonocytic Leukemia. Journal of Hematology & Oncology, 9, 27.
[Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Lee, W.S., Ye, Z., Cheung, A.M.S., Goh, Y.P.S., Oh, H.L.J., Rajarethinam, R., Ye, S.P., Soh, M.K., Chan, E.H.L., Tan, L.K., Tan, S.Y., Chuah, C., Chng, W.J., Connolly, J.E. and Wang, C.I. (2021) Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Molecular Cancer Therapeutics, 20, 1702-1712.
[Google Scholar] [CrossRef]
|
|
[29]
|
He, X., Feng, Z., Ma, J., Ling, S., Cao, Y., Gurung, B., Wu, Y., Katona, B.W., O’Dwyer, K.P., Siegel, D.L., June, C.H. and Hua, X. (2020) Bispecific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia. Blood, 135, 713-723.
[Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Uckun, F.M., Jaszcz, W., Ambrus, J.L., et al. (1988) Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins. Blood, 71, 13-29.
[Google Scholar] [CrossRef]
|
|
[31]
|
Brentjens, R.J., Latouche, J., Santos, E., et al. (2003) Eradication of Systemic B-Cell Tumors by Genetically Targeted Human T Lymphocytes Co-Stimulated by CD80 and Interleukin-15. Nature Medicine, 9, 279-286.
[Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Cooper, L.J.N., Topp, M.S., Serrano, L.M., et al. (2003) T-Cell Clones Can Be Rendered Specific for CD19: Toward the Selective Augmentation of the Graft-versus-B-Lineage Leukemia Effect. Blood, 101, 1637-1644.
[Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Kochenderfer, J.N., Feldman, S.A., Zhao, Y., et al. (2009) Construction and Preclinical Evaluation of an anti-CD19 Chimeric Antigen Receptor. Journal of Immunotherapy (Hagerstown, Md.: 1997), 32, 689-702.
[Google Scholar] [CrossRef]
|
|
[34]
|
Maude, S.L., Teachey, D.T., Porter, D.L., et al. (2015) CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia. Blood, 125, 4017-4023.
[Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Huh, Y.O., Keating, M.J., Saffer, H.L., et al. (2001) Higher Levels of Surface CD20 Expression on Circulating Lymphocytes Compared with Bone Marrow and Lymph Nodes in B-Cell Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 116, 437-443.
[Google Scholar] [CrossRef]
|
|
[36]
|
Borowitz, M.J., Shuster, J., Carroll, A.J., et al. (1997) Prognostic Significance of Fluorescence Intensity of Surface Marker Expression in Childhood B-Precursor Acute Lymphoblastic Leukemia. A Pediatric Oncology Group Study. Blood, 89, 3960-3966.
[Google Scholar] [CrossRef]
|
|
[37]
|
Thomas, D.A., O’Brien, S., Jorgensen, J.L., et al. (2009) Prognostic Significance of CD20 Expression in Adults with De Novo Precursor B-Lineage Acute Lymphoblastic Leukemia. Blood, 113, 6330-6337.
[Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Butler, L.A., Tam, C.S. and Seymour, J.F. (2017) Dancing Partners at the Ball: Rational Selection of Next Generation Anti-CD20 Antibodies for Combination Therapy of Chronic Lymphocytic Leukemia in the Novel Agents Era. Blood Reviews, 31, 318-327.
[Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Watanabe, K., Terakura, S., Martens, A.C., et al. (2015) Target Antigen Density Governs the Efficacy of Anti-CD20- CD28-CD3 Zeta Chimeric Antigen Receptor-Modified Effector CD8+ T Cells. Journal of Immunology (Baltimore, Md.: 1950), 194, 911-920.
[Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Mussai, F., Campana, D., Bhojwani, D., et al. (2010) Cytotoxicity of the Anti-CD22 Immunotoxin HA22 (CAT-8015) against Paediatric Acute Lymphoblastic Leukaemia. British Journal of Haematology, 150, 352-358.
[Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Haso, W., Lee, D.W., Shah, N.N., et al. (2013) Anti-CD22-Chimeric Antigen Receptors Targeting B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 121, 1165-1174.
[Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Fry, T.J., Shah, N.N., Orentas, R.J., et al. (2017) CD22-Targeted CAR T Cells Induce Remission in B-ALL That Is Naive or Resistant to CD19-Targeted CAR Immunotherapy. Nature Medicine, 24, 20-28.
[Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Giordano Attianese, G.M.P., Marin, V., Hoyos, V., et al. (2011) In Vitro and in Vivo Model of a Novel Immunotherapy Approach for Chronic Lymphocytic Leukemia by Anti-CD23 Chimeric Antigen Receptor. Blood, 117, 4736-4745.
[Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Mamonkin, M., Rouce, R.H., Tashiro, H., et al. (2015) A T-Cell-Directed Chimeric Antigen Receptor for the Selective Treatment of T-Cell Malignancies. Blood, 126, 983-992.
[Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Chen, K.H., Wada, M., Pinz, K.G., et al. (2017) Preclinical Targeting of Aggressive T-Cell Malignancies Using Anti-CD5 Chimeric Antigen Receptor. Leukemia, 31, 2151-2160.
[Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Gomes-Silva, D., Srinivasan, M., Sharma, S., et al. (2017) CD7-Edited T Cells Expressing a CD7-Specific CAR for the Therapy of T-Cell Malignancies. Blood, 130, 285-296.
[Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Png, Y.T., Vinanica, N., Kamiya, T., et al. (2017) Blockade of CD7 Expression in T Cells for Effective Chimeric Antigen Receptor Targeting of T-Cell Malignancies. Blood Advances, 1, 2348-2360.
[Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Chen, K.H., Wada, M., Firor, A.E., et al. (2016) Novel Anti-CD3 Chimeric Antigen Receptor Targeting of Aggressive T Cell Malignancies. Oncotarget, 7, 56219-56232.
[Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Hudecek, M., Schmitt, T.M., Baskar, S., et al. (2010) The B-Cell Tumor-Associated Antigen ROR1 Can Be Targeted with T Cells Modified to Express a ROR1-Specific Chimeric Antigen Receptor. Blood, 116, 4532-4541.
[Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Hudecek, M., Lupo-Stanghellini, M., Kosasih, P.L., et al. (2013) Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells. Clinical Cancer Research, 19, 3153-3164.
[Google Scholar] [CrossRef]
|
|
[51]
|
Berger, C., Sommermeyer, D., Hudecek, M., et al. (2015) Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells. Cancer Immunology Research, 3, 206-216.
[Google Scholar] [CrossRef]
|
|
[52]
|
Perera, L.P., Zhang, M., Nakagawa, M., et al. (2017) Chimeric Antigen Receptor Modified T Cells That Target Chemokine Receptor CCR4 as a Therapeutic Modality for T-Cell Malignancies. American Journal of Hematology, 92, 892-901.
[Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Qin, H., Cho, M., Haso, W., et al. (2015) Eradication of B-ALL Using Chimeric Antigen Receptor-Expressing T Cells Targeting the TSLPR Oncoprotein. Blood, 126, 629-639.
[Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Faitschuk, E., Hombach, A.A., Frenzel, L.P., et al. (2016) Chimeric Antigen Receptor T Cells Targeting Fc mu Receptor Selectively Eliminate CLL Cells While Sparing Healthy B Cells. Blood, 128, 1711-1722.
[Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Pinz, K., Liu, H., Golightly, M., et al. (2016) Preclinical Targeting of Human T-Cell Malignancies Using CD4-Specific Chimeric Antigen Receptor (CAR)-Engineered T Cells. Leukemia, 30, 701-707.
[Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Vera, J., Savoldo, B., Vigouroux, S., et al. (2006) T Lymphocytes Redirected against the Kappa Light Chain of Human Immunoglobulin Efficiently Kill Mature B Lymphocyte-Derived Malignant Cells. Blood, 108, 3890-3897.
[Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Ramos, C.A., Savoldo, B., Torrano, V., et al. (2016) Clinical Responses with T Lymphocytes Targeting Malignancy-Associated Kappa Light Chains. The Journal of Clinical Investigation, 126, 2588-2596.
[Google Scholar] [CrossRef]
|